Home
About us
Founded in 2004 and headquartered in Guangzhou Sino-Singapore Knowledge City, Guangzhou Kefang Biotechnology Co., Ltd. is a national high-tech enterprise focusing on the research and development, manufacturing, sales and service of in vitro diagnostic reagents and instruments (IVD). The company has always adhered to the strategy of independent intellectual property rights, independent innovation and independent brand, and has established a biochemical immunologic assembly line platform, chemiluminescence detection platform, fluorescence immunochromatography platform and biochemical diagnostic technology platform. It has obtained more than 200 registration certificates, and the test series covers liver and kidney function, cardiovascular disease, blood lipids, diabetes, genetic diseases, tumors, nail function and other fields, and is widely used in medical institutions and third-party testing centers at all levels across the country.
Read moreNews
Recently, Kefang Biotech won the title of the 20th "Guangdong Youth Civilization" and held an awarding ceremony, attended by the leaders of the Youth League Provincial Committee, the company's leaders, the secretary of the party branch, the secretary of the Youth League Committee and some representatives of the league members.
Read moreProducts & Solutions
Chemiluminescence platform
Fluorescence immunoplatform
Service support
Kefang Biotech has been adhering to the concept of "science and technology benefiting all directions", and has been committed to providing customers with the best quality products and the most exquisite technical services for many years. The company is equipped with strong technical services
Read morehuman resources
Since its establishment in 2004, Kefang has adhered to the management concept of "people-oriented" and pursued the principle of "being responsible for users, creating value for collaborators, and creating a good working environment and development space for employees"
Read moreContact us
2024-10-28 Science and Technology News
Recently, the National Medical Security Administration recently issued the "Notice on Carrying out the Standardized Governance of Medical Service Prices (First Batch)" has blown up the entire IVD circle and attracted widespread attention!
The notice focuses on the following four inspection items to adjust the prices accordingly.
Interpretation of document content:
1 ► Governance target price:Take the national median price, average price or the lowest price of the first price area as the target price, urge the reduction of the high procurement cost of equipment and consumables, and reduce the project price to near the target price.If the current price level is lower than the target price, the price will not be adjusted for the time being.If the price level is indeed low, it can be adjusted appropriately with reference to the governance objectives in the subsequent dynamic adjustment of medical service prices.
2 ► From the table, it can be seen that the fee reduction of these four items in some provinces has basically reached 50%, and the fee reduction for glycated hemoglobin has reached the highest 70%! This price adjustment may bring some changes to the development of testing projects.
3 ►The provincial medical insurance bureaus selected three medical institutions with high medical insurance fund settlement amounts to fill in the "Medical Service Price Composition Questionnaire" to deeply analyze the equipment depreciation and consumables costs in the project price composition, especially whether there is an inflated purchase price of equipment and consumables in high-priced provinces that push up the project price.
4 ► High-priced provinces promptly lowered the high inspection price to the target price of governance, issued a document to implement the first batch of price standardization governance work before October 31, and reported the implementation of the National Medical Security Administration.
5 ►It is necessary to pay close attention to the changes in project service volume and total cost after treatment, prevent the surge in service volume of similar alternative projects, and prevent the disguised resurgence of equipment consumables in the form of declaring new projects after the selection of substitutes.
In order to rectify the current chaotic charging phenomenon, it is believed that there will be more price adjustments for inspection items in the future, and there will be more and more inspection items that need to be uniformly charged. It is the general trend of routine inspection projects to significantly reduce prices and achieve national unified fees in the future, which will further promote the import substitution of domestic brands!
As an IVD company, how should we respond to this major change, actively embrace policies, and jointly promote the high-quality development of China's medical industry?